RhG-CSF

ApprovedSmall molecule

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

RhG-CSF is one of 127 small molecule programs targeting Neutropenia. It is currently in Approved.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

LymphomaActive, not recruiting

Hemophagocytic SyndromeActive, not recruiting

Breast CancerActive, not recruiting

Cervical CancerActive, not recruiting

NeutropeniaPhase 2

Active, not recruiting

LymphomaPreclinical

Active, not recruiting

Hemophagocytic SyndromePreclinical

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Cervical CancerApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

RhG-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Approved

1 2

Tykerb

GSK

Preclinical

80 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Avastin

Prolia

14 6

Gemzar

GGynecologic Oncology Group

Preclinical

22 7

DATROWAY

Daiichi Sankyo

Preclinical

4 8

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 9

Voltaren

Novartis

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma3 trials

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Unknown status·OOu Bai, MD/PHD·N/A·NCT05834751·144 enrolled

PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Unknown status·SSun Yat-sen University·N/A·NCT05156554·80 enrolled

PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Unknown status·PPeking University·Phase 4·NCT02905942·96 enrolled

Cervical Cancer2 trials

To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer

Unknown status·—·Phase 4·NCT03206684·20 enrolled

Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer

Completed·—·Phase 2·NCT04542356·60 enrolled

Neutropenia2 trials

Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma

Unknown status·TThe First Hospital of Jilin University·Phase 2·NCT04460508·170 enrolled

Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

Unknown status·RRuijin Hospital·Phase 4·NCT04083079·250 enrolled

Hemophagocytic Syndrome1 trial

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome

Unknown status·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·N/A·NCT04500886·50 enrolled

Stem Cells1 trial

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Unknown status·—·Phase 4·NCT06026995·174 enrolled

1 more indication

Breast Cancer1 trial

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy

Completed·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 4·NCT02805153·215 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for RhG-CSF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RhG-CSF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RhG-CSF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

RhG-CSF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma3 trials

Cervical Cancer2 trials

Neutropenia2 trials

Hemophagocytic Syndrome1 trial

Stem Cells1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News